Description:
Background
Bacterial infections are considered to be one of the largest challenges in the healthcare system because bacteria can mutate in response to antibiotics. Data from the Centers for Disease Control indicate that at least two million people are infected with antibiotic-resistant bacteria, resulting in at least 23,000 deaths annually.
Data prediction shows that more people will die from these types of infections than all other diseases combined by the year 2050. It is clear that novel approaches are required to treat bacteria without using traditional antibiotics.
 
Technology Overview
One of the more promising methodologies involves the use of metallic nanoparticles, since bacteria do not develop a resistance to these nanostructures as they do to antibiotics. However, metallic nanoparticle synthesis methods are often accompanied by significant drawbacks such as cost, extreme processing conditions, and toxic waste production since they use harsh chemicals such as corrosive agents and strong acids. 
Northeastern researchers have used Escherichia coli, Pseudomonas aeruginosa, Methicillin resistance, Staphylococcus aureus, and S.aureus to synthesize selenium nanoparticles using a novel, environmentally safe approach.
These biogenic selenium nanoparticles are able to reduce bacterial growth without antibiotics, overcoming the drawbacks of synthetic methods that employ toxic chemicals.
 
Benefits
- Selenium nanoparticles are made using eco‑friendly method
- Selenium nanoparticles are of a small and uniform shape, synthesized with a relatively homogeneous size distribution
- Bio‑SeNPs synthesized by S. aureus showed the best cell growth rate at a concentration of 50 mug/mL
 
Applications
- Antibacterial coatings for medical devices
- Antibacterial applications as drug delivery carriers
- Antibacterial treatment for healthcare acquired infections (HAIs)
- Cancer therapeutic
 
Opportunity
- License
- Partnering
- Research collaboration
Patent Information:
Category(s):
1. Life Science
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Thomas Webster
David Medina Cruz
Keywords: